306 results about "Pace maker" patented technology

A cardiac monitoring and treatment apparatus allows a victim of a medical emergency access to a medical professional (MP) who can monitor, diagnose and treat the victim from a remote site. The apparatus includes a cardiac monitoring and treatment device (CMTD) coupled to an electronic adaptor designed to communicate with a local, first transmitting/receiving (T/R) device which, in turn, is adapted to electronically communicate with a remote, second transmitting/receiving (T/R) device used by the MP. The CMPD comprises a cardiac treatment circuit for effecting cardiac pacing and/or defibrillation and a cardiac signal circuit for receiving cardiac signals. The cardiac signals are (1) transmitted from the signal circuit to the second T/R device for evaluation by the MP, (2) the MP may transmit a control signal to the treatment circuit, and (3), in response thereto, the treatment circuit may generate one or more electrical pulses for treatment of the victim.

Systems and methods for providing communications between an external device and first and second leadless pacemakers (LPs) located in a heart are provided. A method includes receiving first and second event messages from the first and second LPs, the first and second event messages received at different points in time at the external device, determining the signal strengths of the first and second event messages, respectively, as received at the external device, adjusting first and second LP discrimination thresholds based on the received signal strengths of the first and second event messages, respectively, and utilizing the first and second LP discrimination thresholds to identify which of the first and second LP transmits subsequent event messages, in order for the external device to independently communicate with the first and second LPs.

Devices and systems for generating energy for powering implanted medical devices such as a pacemakers and defibrillators.

A system (10) for achieving a desired cardiac rate and cardiac rhythm in response to atrial fibrillation in a heart includes an atrial fibrillation (AF) detector (40) for detecting AF. The system also includes an atrioventricular node vagal stimulator (AVN-VS) (30) for stimulating vagal nerves associated with an atrioventricular (AV) node of the heart. The system further includes an on-demand pace maker (40) for providing ventricular pacing stimulation to the heart. A control unit (20) is operatively connected with the AF detection device, the AVN-VS device, and the on-demand pacing device. The control unit is responsive to AF detection by the AF detector to cause the AVN-VS to stimulate the vagal nerves to help reduce the ventricular rate of the heart. The control unit is further responsive to AF detection by the AF detector to cause the on-demand pace maker to help regulate the ventricular rate of the heart.

Disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, i.e., the administered composition functions as a biological pacemaker.

Techniques are provided for detecting atrial fibrillation (AF) based on variations in ventricular intervals detected by a pacemaker, implantable cardioverter-defibrillator (ICD) or implantable cardiac monitor (ICM). In one example, ventricular beats are detected and intervals between the ventricular beats are measured, such as RR intervals. Irregular ventricular beats are identified, including ectopic beats, bigeminal beats, and the like. The degree of variability within the ventricular intervals is then determined while excluding any intervals associated with irregular beats. AF is then detected based on the degree of variability. That is, AF is detected based on variability occurring within ventricular intervals after ectopic beats and other irregular beats have been eliminated, thus mitigating detection problems that might arise if the variability were instead calculated based on all ventricular beat intervals. Techniques are also described herein for distinguishing AF from sinus tachycardia, which can also cause a high degree of variability in RR intervals.

An apparatus is provided for reducing the formation and migration of blood clots from an atrial appendage, such as the left atrial appendage, to the blood vessel system of a patient. The apparatus comprises an atrial pacer to treat non-rheumatic atrial fibrillation (NRAF) of an atrial appendage so that the formation blood clots within the atrial appendage is decreased or eliminated. In addition, the apparatus includes a blood clot filter supported by the atrial pacer proximate the atrial appendage and the atrium to reduce the migration of blood clots from the atrial appendage into the blood vessel system of a patient.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

An implantable medical electrode device, in particular a cardiovascular cardiac pacemaker or defibrillator electrode device, comprises an elongate, tubular electrode body (2), a fixing zone (4) in front of the distal end (3) of the electrode body (2), in which the externally closed peripheral envelope (8) of the electrode body (2) is reversibly expandable into a body lumen (27) for detachable fixing of the electrode device (1), and expansion means, situated in the fixing zone (4), for controlling the expansion and contraction in the fixing zone (4).

Disclosed is a system for the detection of cardiac events (a guardian system) that includes an implanted device called a cardiosaver, a physician's programmer and an external alarm system. The system is designed to provide early detection of cardiac events such as acute myocardial infarction or exercise induced myocardial ischemia caused by an increased heart rate or exertion. The system can also alert the patient with a less urgent alarm if a heart arrhythmia is detected. Using one or more detection algorithms, the cardiosaver can detect a change in the patient's electrogram that is indicative of a cardiac event within five minutes after it occurs and then automatically warn the patient that the event is occurring. To provide this warning, the guardian system includes an internal alarm sub-system (internal alarm means) within the cardiosaver and/or an external alarm system (external alarm means). If the guardian system is put into a pacemaker, the algorithm can utilize a different analysis of the electrogram depending on whether or not the pacemaker is actually pacing the heart.

An implantable bi-ventricular heart stimulating device and system, suitable for treating congestive heart failure, have a control circuit with first and second pacing circuits and first and second sensing circuits. The device operates with time cycles corresponding to normal heart cycles. The control circuit determines: (a) whether a signal typical of an evoked response to a pacing pulse delivered by the first pacing circuit is sensed within a first time interval and (b) whether a signal typical for an R-wave transferred from the second ventricle, or from some other part of the heart, to the first ventricle is detected within a first time window. The operation of the device depends on whether the conditions (a) and (b) are fulfilled.

Cell transplantation for constructing biological heart pacemaker is used embryo source dry/ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

A package pacer is configured for use with an automatic strapping machine having a strap chute through which strap material is fed and from which strap material is tensioned onto a package. The strapping machine has an in-feed conveyor defining a plane and is configured to automatically move a package into a packaging region bounded by the chute. The pacer includes a frame that is mountable to the strapping machine. A plurality of rollers are mounted to the frame in a stationary plane about coplanar with the in-feed conveyor plane. The rollers extend forwardly of the strapping machine and permit conveyance of the package therealong and onto the in-feed conveyor. A pacing element is movable between a stop position in which the pacer element is out of the in-feed conveyor plane and interferes with movement of the package onto the in-feed conveyor and a feed position in which the pacing element resides about coplanar with the planar stationary rollers and the in-feed conveyor. A drive moves the pacing element between the stop position and the feed position.

A system (10) for achieving a desired cardiac rate and cardiac rhythm in response to atrial fibrillation in a heart includes an atrial fibrillation (AF) detector (40) for detecting AF. The system also includes an atrioventricular node vagal stimulator (AVN-VS) (30) for stimulating vagal nerves associated with an atrioventricular (AV) node of the heart. The system further includes an on-demand pace maker (40) for providing ventricular pacing stimulation to the heart. A control unit (20) is operatively connected with the AF detection device, the AVN-VS device, and the on-demand pacing device. The control unit is responsive to AF detection by the AF detector to cause the AVN-VS to stimulate the vagal nerves to help reduce the ventricular rate of the heart. The control unit is further responsive to AF detection by the AF detector to cause the on-demand pace maker to help regulate the ventricular rate of the heart.

The invention relates to a non-invasive attached telemetering electrocardiographic recording method having an ultra-long record period and an ultra-high storage capacity. By using the method, characteristic values of electrocardiographic waves can be safely, stably and clearly acquired under the natural physiological state of a human body within a long period (more than 15 days), microvolt-level measurements of T-wave alternans can be acquired, and the collection, processing and high-capacity storage of electrocardiographic waves can be completed; and multiple electrocardiographic recording pasters can be used to realize the simultaneous recording of multi-channel body surface electrocardiograms, and a computer data processing and analysis system can complete the data monitoring and analysis, image display, data storage and printing and output of the recorded signals and realize the networking transmission of the electrocardiosignals. The clinical indications of the device include: symptoms related to suspected arrhythmia; determination of arrhythmia property, and completion of reasonably evaluating anti-arrhythmia treatment and monitoring myocardial ischemia; evaluation of anemic heart disease treatment measures; instructions to acute myocardial infarction patients before leaving hospital and during convalescence; and installation, detection and function assessment of sudden cardiac death and heart pacemakers.

The present invention is directed toward methods for regulating biological pacemaking activity and devices used in such regulation. Such regulation can be accomplished by introducing genetic material to the heart by transfecting heart cells of the atrium or ventricle with an oligonucleotide, small interfering RNA, that silence KCNJ2, and suppress the I_K1 current. Suppression (or silencing) of KCNJ2 subsequently induces pacemaker-like activities in previously regular myocytes. This invention provides for methods of targeted delivery using a fluid delivery catheter. Such a catheter allows the targeting of a specific area in the atrium or the ventricle of the heart. Also, combination methods of treating arrhythmia with traditional device-based therapies (e.g., pacemakers and defibrillators) and an oligonucleotide of the subject invention.

The invention provides a heart pacing device, and a fixing method and a conveying system thereof; the heart pacing device comprises an annular support and a wireless pacing unit at least partially arranged on the annular support; the annular support has a first size with the rebound limited by the first environment, and expands to a second size under the second environment. The heart pacing devicecan be fixed in human body tissues of different wall thicknesses and sizes, and can be easily fixed in a boundary place between the postcava and the right atrium, realizing dual-cavity pacing of thewireless pacing unit, and ensuring the atrium-chamber synchronization physiological pacing. The heart pacing device uses the self-expansion features of the annular support to tightly attach the annular support with protogenesis blood vessel walls, thus fixing the heart pacing device in the heart chamber with a good fixing effect, and preventing heart chamber perforating risks.